Annual prevalence of sustained and episodic LABA monotherapy among the population at risk (n=5592 patients receiving a separate LABA inhaler) including odds ratios from multilevel logistic regression analysis
| Variable (no. of patients) | Sustained monotherapy (n=324) | Episodic monotherapy (n=667) | ||||
|---|---|---|---|---|---|---|
| Prevalence (%) | Univariate OR (95% CI) | Multivariate OR (95% CI) | Prevalence (%) | Univariate OR (95% CI) | Multivariate OR (95% CI) | |
| Patient level | ||||||
| Age (years) | ||||||
| 5–11 (455) | 3.3 | 0.49 (0.27 to 0.91) | – | 10.5 | 0.98 (0.67 to 1.44) | – |
| 12–17 (579) | 6.2 | 0.97 (0.61 to 1.54) | – | 10.9 | 1.05 (0.74 to 1.50) | – |
| 18–29 (736) | 6.3 | 1.00 | – | 10.5 | 1.00 | – |
| 30–39 (942) | 7.7 | 1.26 (0.85 to 1.87) | – | 12.4 | 1.24 (0.91 to 1.69) | – |
| 40–49 (815) | 4.5 | 0.71 (0.45 to 1.12) | – | 12.1 | 1.16 (0.84 to 1.59) | – |
| 50–59 (721) | 6.4 | 1.08 (0.70 to 1.67) | – | 14.6 | 1.47 (1.07–2.02) | – |
| 60–69 (614) | 4.7 | 0.78 (0.48 to 1.27) | – | 12.7 | 1.22 (0.87 to 1.71) | – |
| ≥70 (730) | 5.8 | 0.92 (0.59 to 1.44) | – | 11.0 | 1.04 (0.75 to 1.46) | – |
| Sex | ||||||
| Men (2124) | 6.1 | 1.00 | – | 12.7 | 1.00 | – |
| Women (3468) | 5.6 | 0.91 (0.72 to 1.15) | – | 11.4 | 0.88 (0.75 to 1.04) | – |
| Deprivation | ||||||
| 1 affluent (981) | 5.8 | 1.00 | – | 15.0 | 1.00 | 1.00 |
| 2 (1275) | 5.6 | 0.87 (0.58 to 1.30) | – | 11.5 | 0.73 (0.57 to 0.94) | 0.74 (0.58 to 0.96) |
| 3 (1351) | 6.4 | 1.02 (0.68 to 1.54) | – | 12.0 | 0.78 (0.61 to 1.01) | 0.78 (0.61 to 1.00) |
| 4 (1009) | 5.4 | 0.77 (0.49 to 1.19) | – | 12.1 | 0.76 (0.58 to 1.00) | 0.75 (0.58 to 0.99) |
| 5 deprived (976) | 5.6 | 0.79 (0.51 to 1.24) | – | 9.1 | 0.56 (0.42 to 0.74) | 0.56 (0.42 to 0.75) |
| Asthma review | ||||||
| Not reviewed (509) | 11.2 | 1.00 | 1.00 | 10.0 | 1.00 | – |
| Reviewed (5083) | 5.3 | 0.44 (0.32 to 0.60) | 0.44 (0.32 to 0.61) | 12.1 | 1.16 (0.85 to 1.57) | – |
| Practice level | ||||||
| Dispensing | ||||||
| No (5331) | 5.7 | 1.00 | – | 12.2 | 1.00 | 1.00 |
| Yes (222) | 8.1 | 1.47 (0.80 to 2.69) | – | 6.8 | 0.54 (0.31 to 0.92) | 0.52 (0.30 to 0.90) |
| Contract | ||||||
| nGMS (5046) | 5.5 | 1.00 | 1.00 | 11.8 | 1.00 | – |
| 2c or 17c (507) | 8.9 | 1.51 (0.95 to 2.40) | 1.47 (0.92 to 2.34) | 13.2 | 1.17 (0.88 to 1.56) | – |
| Single handed | ||||||
| No (5425) | 5.8 | 1.00 | – | 12.0 | 1.00 | 1.00 |
| Yes (128) | 7.8 | 1.44 (0.67 to 3.09) | – | 8.6 | 0.70 (0.37 to 1.33) | 0.77 (0.41 to 1.46) |
There were no significant differences in the following practice characteristics with either sustained or episodic monotherapy: list size, post-graduate training status, maximum points for quality and outcomes framework medicines 10, 11 and 12, and remoteness. Contract status was non-significant following adjusted analysis of sustained monotherapy but was included in the final model due to improved model fit. Singled handed practice was non-significant following adjusted analysis of episodic monotherapy but was included in the final model due to improved model fit.
LABA, long-acting β2 agonist; nGMS, new General Medical Services.